Phase I trial and tumour localisation of the anti-EGFR monoclonal antibody ICR62 in head and neck or lung cancer
Authors:
- H ModjtahediHMH Modjtahedi
- T HickishTHT Hickish
- M NicolsonMNM Nicolson
- J MooreJMJ Moore
- J StylesJSJ Styles
- S EcclesSES Eccles
- E JacksonEJE Jackson
- J SalterJSJ Salter
- J SloaneJSJ Sloane
- L SpencerLSL Spencer
- K PriestKPK Priest
- I SmithISI Smith
Open Access
- 1 January 1996
- journal article
- clinical trial
- Published by Springer Nature in British Journal of Cancer
- Vol. 73 (2) , 228-235
Abstract
The purpose of this study was to determine the effect of the first rat monoclonal antibody (MAb ICR62) to the epidermal growth factor receptor (EGFR) in a phase I clinical trial in patients with unresectable squamous cell carcinomas. This antibody effectively blocks the binding of EGF, transforming growth factor (TGF)-alpha and HB-EGF to the EGFR, inhibits the growth in vitro of tumour cell lines which overexpress the EGFR and eradicates such tumours when grown as xenografts in athymic mice. Eleven patients with squamous cell carcinoma of the head and neck and nine patients with squamous cell carcinoma of the lung, whose tumours expressed EGFR, were recruited. Groups of three patients were treated with 2.5 mg, 10 mg, 20 mg or 40 mg of ICR62 and a further eight patients received 100 mg. All patients were evaluated for toxicity using WHO criteria. Patients' sera were tested for the clearance of MAb ICR62 and the development of human anti-rat antibodies (HARA). No serious (WHO Grade III-IV) toxicity was observed in patients treated with up to 100 mg of antibody ICR62. Antibody ICR62 could be detected at 4 h and 24 h in the sera of patients treated with 40 mg or 100 mg of ICR62. Only 4/20 patients showed HARA responses (one at 20 mg, one at 40 mg and two at 100 mg doses) and of these only the former two were anti-idiotypic responses. In four patients receiving doses of ICR62 at 40 mg or greater, biopsies were obtained from metastatic lesions 24 h later and examined for the localisation of ICR62 using anti-rat antibody reagent. In these patients we showed the localisation of MAb ICR62 to the membranes of tumour cells; this appeared to be more prominent at the higher dose of 100 mg. On the basis of these data we conclude that MAb ICR62 can be administered safely to patients with squamous cell carcinomas and that it can localise efficiently to metastases even at relatively low doses.Keywords
This publication has 32 references indexed in Scilit:
- The Binding of HB-EGF to Tumor Cells Is Blocked by mAbs Which Act as EGF and TGFα AntagonistsBiochemical and Biophysical Research Communications, 1995
- Randomised trial of monoclonal antibody for adjuvant therapy of resected Dukes' C colorectal carcinomaThe Lancet, 1994
- Immunotherapy with antibodies to the EGF receptorInternational Journal of Cancer, 1994
- Betacellulin: a mitogen from pancreatic beta cell tumorsScience, 1993
- Cancer Progression and Growth: Relationship of Paracrine and Autocrine Growth Mechanisms to Organ Preference of MetastasisExperimental Cell Research, 1993
- Malignant astrocytomas treated with iodine-125 labeled monoclonal antibody 425 against epidermal growth factor receptor: A phase II trialInternational Journal of Radiation Oncology - Biology - Physics (IJROBP), 1992
- Structure and Function of Human Amphiregulin: A Member of the Epidermal Growth Factor FamilyScience, 1989
- Radioimmunoscintigraphy of squamous carcinomas of the head and neckHead & Neck Surgery, 1987
- RECEPTORS FOR EPIDERMAL GROWTH FACTOR AND OTHER POLYPEPTIDE MITOGENSAnnual Review of Biochemistry, 1987
- Autocrine growth factors and cancerNature, 1985